Skip to main content
Erschienen in: BMC Cancer 1/2020

Open Access 01.12.2020 | Database

Construction of an integrated human osteosarcoma database, HOsDb, based on literature mining, microarray analysis, and database retrieval

verfasst von: Yifu Sun, Lishan Wang, Changkuan Li, Rui Gu, Weidong Zang, Wei Song, Peng Xia

Erschienen in: BMC Cancer | Ausgabe 1/2020

Abstract

Background

Osteosarcoma (OS) is the most frequent primary malignancy of bone with a high incidence in adolescence. This study aimed to construct a publicly available, integrated database of human OS, named HOsDb.

Methods

Microarray data, current databases, and a literature search of PubMed were used to extract information relevant to human OS-related genes and their transcription factors (TFs) and single nucleotide polymorphisms (SNPs), as well as methylation sites and microRNAs (miRNAs). This information was collated for constructing the HOsDb.

Results

In total, we identified 7191 OS tumor-related genes, 763 OS metastasis-related genes, and 1589 OS drug-related genes, corresponding to 190,362, 21,131, and 41,135 gene-TF pairs, respectively, 3,749,490, 358,361, and 767,674 gene-miRNA pairs, respectively; and 28,386, 2532, and 3943 SNPs, respectively. Additionally, 240 OS-related miRNAs, 1695 genes with copy number variations in OS, and 18 genes with methylation sites in OS were identified. These data were collated to construct the HOsDb, which is available at www.​hosdatabase.​com. Users can search OS-related molecules using this database.

Conclusion

The HOsDb provides a platform that is comprehensive, quick, and easily accessible, and it will enrich our current knowledge of OS.
Begleitmaterial
Hinweise
Yifu Sun and Lishan Wang are the co-first authors

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12885-020-06719-2.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
CGH
Comparative genomic hybridization
CNV
Copy number variations
DEG
Differentially expressed gene
DEM
Differentially expressed miRNA
FDR
False discovery rate
GEO
Gene Expression Omnibus
HOsDb
human OS database
miRNA
microRNA
OS
Osteosarcoma
SNP
Single nucleotide polymorphism
TF
Transcription factor

Background

Osteosarcoma (OS), the most frequent primary malignancy of bone, commonly occurs in the metaphyseal region of the long bones, developing at sites of rapid bone growth [1]. OS commonly affects children, adolescents, and young adults. The annual incidence of OS in the general population is 2–3/million/year, while in adolescence, especially from 15 to 19 years of age, OS incidence reaches 8–11/million/year [2]. OS accounts for 15% of all solid extracranial cancers in people aged 15–19 years [3]. OS can be divided into several subtypes, such as osteoblastic, chondroblastic, fibroblastic, small cell, telangiectatic, high-grade surface, extra-skeletal, and other lower-grade forms, including periosteal and parosteal [4]. Some OS cases are likely to have a genetic basis, and numerous hereditary disorders associated with germline alterations of tumor suppressor genes have been found in patients with OS, such as hereditary retinoblastoma [5] and Li-Fraumeni cancer family syndrome [6, 7]. However, the mechanisms underlying the pathogenesis of OS remain largely unclear.
Many databases have been developed to investigate the association between certain molecules of interest and disease pathogenesis from different perspectives. For instance, Online Mendelian Inheritance in Man (OMIM) [8] contains information on the relationship between the phenotype and genotype of all known Mendelian disorders. Wikigenes [9] is a portal that provides information about genes, proteins, chemical compounds and their reported associations with various diseases. The miR2Disease [10] and Human microRNA Disease Database (HMDD) [11] aim to provide comprehensive collection of microRNAs (miRNAs) associated with various human diseases. MethyCancer [12] contains highly integrated data regarding cancer-related genes, DNA methylation sites, and information on cancer from public resources. TRANSFAC is a database of transcription factors (TFs), which offers an integrated system for predicting gene expression regulation [13]. Although research data regarding OS has accumulated during the past decades, to the best of our knowledge, there is only one available database specifically focusing on OS molecular biology, called Osteosarcoma Database [14]. Nevertheless, only 911 OS-associated genes and 81 miRNAs collected through manual literature mining are included in this database, and there is no information available regarding other OS-related molecules, such as TFs or methylation sites [14]. The development of high-throughput laboratory techniques, such as microarray analysis, has enabled generation of large quantities of data associated with OS, which are an important resource for exploration of potential OS-related molecules, including genes, miRNAs, and copy number variations (CNVs) [1518]. While these data provide insight into certain aspects of OS, they are not assembled together in a structured format. Thus, there is a need to establish an integrated, OS-specific database or platform of OS-related genes, TFs, methylation sites, and miRNAs.
We collected detailed OS-related data, including OS-related genes, TFs, single nucleotide polymorphisms (SNPs), miRNAs, methylation sites, and CNVs by analyzing several microarray deposits in the Gene Expression Omnibus (GEO) data repository, searching current databases, and mining the literature in PubMed. Using these data, we aimed to construct a publicly available, integrated database of human OS to facilitate the exploration of human OS-related molecules and create a unique resource for research into this disease.

Construction and content

Database construction

The integrated database of human OS, named HOsDb, aims to provide a high-quality collection of human OS-related genes, methylation sites, CNVs, miRNAs, TFs, and SNPs based on literature mining, microarray analysis, and database retrieval. The data collection and processing steps are illustrated in Fig. 1.
Initially, mRNA expression microarrays related to OS were downloaded from the GEO database [19]. Detailed information regarding the datasets used, such as the GEO accession number and sample type and size, is shown in Table 1. The corresponding experimental conditions were tumor vs. normal, metastasis vs. non-metastasis, or drug-treated vs. untreated. Raw Affymetrix data in CEL file format were read using Affy [20] and normalized using the robust microarray analysis (RMA) method [21]. The downloaded normalized expression matrix was used for analysis of data generated using Illumina and Agilent platforms. Differentially expressed genes (DEGs), defined as OS-related DEGs, were identified using the Linear Models for Microarray and RNA-Seq Data (limma) package [22] with a cut-off value of |log fold change (FC)| > 1 and false discovery rate (FDR) [23] < 0.05. A total of 6964 OS tumor-related, 685 OS metastasis-related, and 1589 OS drug-related DEGs were identified (Table 2). Literature mining of the PubMed collection was used to generate a list of known OS tumor-related and OS metastasis-related genes. A total of 505 genes related to OS tumor and 87 genes related to OS metastasis were found in the published literature. A list of OS-related genes was then collated by integrating OS-related DEGs identified by microarray analysis and OS-related genes identified by literature mining. Using this approach, 7191 OS tumor-related genes (Supplementary Table 1), 763 OS metastasis-related genes, and 1589 OS drug-related genes were identified (Table 2).
Table 1
Information of the included datasets
Category
GEO accession number
Platform
Sample type
Sample size
Experiment design
Gene
Tumor vs. normal
GSE11414
GPL6244
Cell lines
Tumor: 4; normal: 2
genome-wide comparison of gene expression and identified genes that are differentialy expressed in osteosarcoma (U2OS, MG63) cell lines relative to normal human osteoblasts (HOB)
GSE12865
GPL6244
Tumor tissues and normal cell line
Tumor: 12; normal: 2
genome-wide comparison of gene expression and identified genes that are differentialy expressed in osteosarcoma tumour samples relative to normal human osteoblasts (HOB)
GSE14359
GPL96
Tumor tissues and normal cell line
Tumor: 18; normal: 2
mRNA from 5 frozen conventional osteosarcoma and 4 osteosarcoma lung metastases tumor samples and mRNA from fresh primary osteoblast cells (HOB) were extracted and hybridized to HG U133A microarrays
GSE16088
GPL96
Tumor and normal tissues, as well as tumor cell lines
Tumor: 17; normal: 6
Profiles of human osteosarcoma and three normal tissues, single channel design
GSE19276
GPL6848
Tumor and normal tissues
Tumor: 44; normal: 5
Gene expression profiling of primary osteosarcoma biopsies and compared the results to gene expression profiling of non-malignant bone to identify differentially expressed genes unique to OS in the context of the bone micorenvironment
GSE28424
GPL13376
Tumor cell lines and normal tissues
Tumor: 19; normal: 4
19 osteosarcoma cell lines, 4 normal bones used as controls. No replicates. The group of osteosarcomas are compared to the group of normal bones.
GSE30807
GPL570
Tumor cell lines and normal bone mesenchymal stem cells
Tumor: 2; normal: 1
To analysis stem/progenitor cell-associated genes and molecules involved in regulation of self-renewal signaling pathways of cancer stem cells between UT2 cells and its parent cells: U2OS (MSC works as positive control here)
GSE36001
GPL6102
Tumor cell lines and normal osteoblast and bone cells.
Tumor: 19; normal: 6
Comparison of gene expression patterns in 19 osteosarcoma cell lines and 6 normal samples (osteoblasts and bones)
GSE42352
GPL10295
Tumor cell lines, pre-chemotherapy biopsies, osteoblasts, mesenchymal stem cells
Tumor: 103; normal: 15
Gene set analysis on previously published genome-wide gene expression data of osteosarcoma cell lines (n = 19) and osteosarcoma pre-chemotherapy biopsies (n = 84), and characterizing expression of the insulin-like growth factor receptor signaling pathways in human osteosarcoma as compared with osteoblasts and with the hypothesized progenitor cells of osteosarcoma - mesenchymal stem cells.
GSE56001
GPL10558
Tumor cells and normal mesenchymal stem cells
Tumor: 3; normal: 9
Analysis of gene changes in different genes modulation in mesenchymal stem cells and compared to primary human osteosarcoma cells
GSE9508
GPL6076
Tumor and normal biopsies
Tumor: 34; normal: 5
Two-colour experiment. 7 samples for non-metastatic patients, 6 of which are analyzed in duplicate (dye-swaps); 11 samples for metastatic patients, 10 of which are analyzed in duplicate (dye-swaps); 5 samples of non-malignant bone analyzed individualy, no dye-swaps (i.e. 5 biological replicates).
Metastasis vs. non-metastasis
GSE14359
GPL96
Conventional osteosarcoma and lung metastases tumor samples
Metastasis: 8; non-metastasis: 10
mRNA from 5 frozen conventional osteosarcoma and 4 osteosarcoma lung metastases tumor samples and mRNA from fresh primary osteoblast cells (HOB) were extracted and hybridized to HG U133A microarrays
GSE18947
GPL570
Low and high metastatic potential cell sublines
Low metastasis: 3; high metastasis: 3
The assay was performed among three pairs of cublines, the first two pairs of sublines comes from the different passage of sublines established with orthotopic transplantation under the established cell line named Sosp-9607, the other pair was screened by the tail-vein injection method of commercial avaliable cell line-Saos-2.
GSE21257
GPL10295
Metastatic and non-metastatic tumor biopsies
Metastasis: 34; non-metastasis: 19
Pre-chemotherapy biopsies of osteosarcoma patients who developed metastases within 5 yrs. (n = 34) were compared with pre-chemotherapy biopsies of osteosarcoma patients who did not develop metastases within 5 yrs. (n = 19)
GSE9508
GPL6076
Metastatic and non-metastatic tumor biopsies
Metastasis: 21; non-metastasis: 13
Two-colour experiment. 7 samples for non-metastatic patients, 6 of which are analyzed in duplicate (dye-swaps); 11 samples for metastatic patients, 10 of which are analyzed in duplicate (dye-swaps); 5 samples of non-malignant bone analyzed individualy, no dye-swaps (i.e. 5 biological replicates).
Drug-treated vs. untreated
GSE16089
GPL570
Methotrexate-sensitive and –resistant Saos-2 cells
Methotrexate-sensitive samples: 3; methotrexate-resistant samples: 3
Two cell lines are compared, which are Saos-2 osteosarcoma cells sensitive to methotrexate and Saos-2 cells resistant to 10e-6 M methotrexate. Six samples are provided which correspond to triplicates of each cell line.
GSE24401
GPL1456
Atorvastatin-treated and -untreated Saos-2 cells
Atorvastatin-treated samples: 3; atorvastatin-untreated samples: 3
Dye balance-experiment comparing atorvastatin treated Saos-2 cells versus untreated cells at 6, 15 and 24 h using 2 biological replicates
miRNA
GSE28423
GPL8227
Tumor cell lines and normal bones
Tumor cell lines: 19; normal bones: 4
19 osteosarcoma cell lines, 4 normal bones used as controls. No replicates. The group of osteosarcomas are compared to the group of normal bones.
CNV
GSE12830
GPL4091, GPL9128
Tumor tissues
20
Integrative whole-genome analysis of DNA copy number, promoter methylation and gene expression using 10 osteosarcomas with 2 biological replicates
GSE7077
GPL2879
Four osteosarcoma-derived cell lines: U-2 OS, HOS, MG-63 and SAOS-2
4
To utilize oligonucleotide array CGH to identify microaberrations in osteosarcomas, likely to contain genes involved in osteosarcoma tumor oncogenesis. A better understanding of the underlying molecular genetic events leading to tumor initiation and progression could result in the identification of prognostic markers and therapeutic targets.
GSE9654
GPL2879
 
10
To utilize oligonucleotide array CGH and FISH analysis to derive possible genomic signatures of chromosomal instability in osteosarcoma tumors
“-” in the column of “PubMed ID” means that there is no published study so far. GEO Gene Expression Omnibus, CGH Comparative genomic hybridization, FISH Fluorescence in situ hybridization
Table 2
Results of data collection and analysis
 
Tumor vs. normal
Metastasis vs. non-metastasis
Drug-treated vs. untreated
OS-related gene
 DEG (mRNA expression microarray)
6964
685
1589
 Known gene (text mining)
505
87
 Total OS-related gene
7191
763
1589
  Gene-TF pair (database)
190,362
21,131
41,135
  Gene-miRNA pair (database)
3,749,490
358,361
767,674
  Gene-SNP (database)
28,386
2532
3943
OS-related miRNA
 DEM (miRNA expression microarray)
209
 miRNA (database)
31
 Total OS-related miRNA
240
  
OS-related CNV
 CNV (CGH microarray)
1695
OS-related methylation
 Gene methylation (database)
18
OS Osteosarcoma, DEG Differentially expressed gene, DEM Differentially expressed miRNA, miRNA microRNA, CNV Copy number variation, CGH Comparative genomic hybridization
A list of TFs targeting OS-related genes was obtained from the TRANSFAC [24] and ENCODE databases [25]. We found 299 OS tumor-, 207 OS metastasis-, and 194 OS drug-related TFs, which corresponded to 190,362, 21,131, and 41,135 gene-TF pairs, respectively (Table 2). The miRNAs targeting OS-related genes were extracted from existing databases, including miRanda (Good mirSVR score part; release: August 2010) [26], miRecords (version 4) [27], miRTarget2 (version 4) [28], miRWalk (validated targets only) [29], and TargetScan (release 6.2) [30]. A total of 3,749,490, 358,361, and 767,674 gene-miRNA pairs related to OS tumor, metastasis, and drug treatments, respectively, were identified (Table 2). SNPs in OS-related genes were extracted from the National Center for Biotechnology Information (NCBI) dbSNP database (updated on 2014.05.29) [31]. We found 28,386, 2532, and 3943 SNPs in genes related to OS tumor, metastasis, and drug treatment, respectively (Table 2).
Normalized miRNA expression microarray data related to OS were also downloaded from the GEO database (Table 1). Differentially expressed miRNAs (DEMs) were identified using the limma package with a cutoff value of |logFC| > 1 and FDR < 0.05. Known OS-related miRNAs were extracted from the miR2Disease database (updated on 2011.04.14) [10] and HMDD database (updated on 2012.09.09) [11]. In total, 209 OS-related DEMs were identified based on miRNA expression microarray, and 31 known OS-related miRNAs were identified in the miR2Disease and HMDD databases, generating a final count of 240 OS-related miRNAs for inclusion (Table 2).
Normalized, comparative genomic hybridization (CGH) microarray data were downloaded from the GEO database (Table 1) and analyzed using DNAcopy [32] and cghMCR packages [33]. The criteria were set at (Segment Gain or Loss (> 0.2 and incidence > 30%. A total of 1695 genes with CNVs in OS were identified (Table 2).
MethyCancer [12] and PubMeth [34] databases were searched using the keyword “osteosarcoma.” Eighteen genes with methylation sites related to OS were identified for further analysis (Table 2).

Data storage

The data obtained using the methods described were collated and used to construct the integrated human OS database (HOsDb), which is available for use at www.​hosdatabase.​com. HOsDb is a one-stop comprehensive platform for OS researchers.

Database description

The HOsDb is a search engine that can be used to search detailed information on each OS-related term stored in the database. Terms include ‘Home,’ ‘Introduction,’ ‘Tumor vs. normal,’ ‘Metastasis vs. non,’ ‘Drug-treated vs. untreated,’ ‘miRNA,’ ‘copy number variation,’ ‘methylation,’ ‘Related database,’ and ‘Download.’ The ‘Tumor vs. normal,’ ‘Metastasis vs. non,’ and ‘Drug-treated vs untreated’ terms on the home page focus on OS-related genes, as well as TFs, miRNAs and SNPs targeting OS-related genes. Users can query a gene symbol in the search bar located at the top of the linked pages. After inputting the gene symbol, all information related to that gene will be displayed in a new page, including gene/TF/miRNA/SNP symbol, synonyms, full name, logFC, p-value, GEO microarray ID, gene/miRNA regulation direction in OS, miRNA targets, and links to publications in PubMed. To see more details about their gene of interest, users can click on the gene symbol link, and the NCBI page and results related to the gene of interest will appear (Fig. 2). The ‘miRNA’ term links users to a list of OS-related miRNAs, and users can search a particular miRNA by inputting its symbol in the search bar. Notably, users can define their own thresholds (logFC and p-value) for gene or miRNA expression. However, the default settings are logFC > 1 and p-value < 0.05 (Fig. 3a). The ‘copy number variation’ term generates a list of genes with CNVs in OS. Users can query whether a certain gene undergoes changes in copy number in OS or not by inputting the corresponding gene ID or symbol (Fig. 3b). The ‘methylation’ term lists all genes with methylation sites related to OS. Users can input a gene symbol to check whether its sequence has methylation sites in OS or not (Fig. 3c). The ‘Related database’ terms include several internal resources or databases, which are cross-linked in HOsDb, including NCBI, miRBase, HMDD, miR2Disease, MethyCancer, PubMeth, TargetScan, ENCODE, TRANSFAC, miRWalk, miRTarget2, miRecords, and miRanda. The ‘Download’ term allows users to obtain detailed information regarding DEGs, DEMs, TFs, SNPs, and CNVs that was used for HOsDb construction.

Utility and discussion

Compared with a previously established OS database [14], the HOsDb provides more information. For example, our analyses of mRNA and miRNA expression microarrays, and CGH microarray provide a comprehensive list of candidate genes, miRNAs, and CNVs, which will assist users to navigate through the complexity of OS. Moreover, the HOsDb contains detailed gene regulation information, such as potential TF- and miRNA-gene pairs associated with OS, which is convenient for the identification of novel gene relationships involved in OS. Furthermore, information regarding SNPs in OS-related genes is provided in the HOsDb, which will help direct further studies of OS-related SNPs. The OS-related CNVs listed in the HOsDb were generated through analysis of three CGH microarray datasets. Thus, they are more reliable than those generated from a single dataset. Additionally, the HOsDb incorporates a user-friendly interface, which makes all the features easily accessible.
Although data in the HOsDb were collected using a number of different platforms and approaches, all data were normalized prior to analysis, thus adding to the reliability of our results. However, microarray data regarding OS are likely to be constantly updated in the GEO database and next-generation sequencing studies can also provide OS-related data, which will provide new insights into OS biology. This updated information will need to be added to HOsDb, once it is available. Although the HOsDb has advantages over the only other known OS-related database in its current form, we plan to update the database periodically to consistently maintain the quality of OS-related data available, and thus, keep up to date with changes and improvements in the field.

Conclusions

The HOsDb provides a one-stop, comprehensive platform for human OS research that is quick and easily accessible. We believe that the HOsDb will be particularly attractive to communities and researchers interested in OS, and that the HOsDb will considerably facilitate research regarding the pathogenesis of OS.

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12885-020-06719-2.

Acknowledgements

Not applicable.
Not applicable.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Anhänge

Supplementary information

Literatur
1.
Zurück zum Zitat Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722.CrossRef Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722.CrossRef
2.
Zurück zum Zitat Ritter J, Bielack S. Osteosarcoma. Ann Oncol. 2010;21(suppl_7):vii320–5.CrossRef Ritter J, Bielack S. Osteosarcoma. Ann Oncol. 2010;21(suppl_7):vii320–5.CrossRef
3.
Zurück zum Zitat Stiller C, Bielack S, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978–1997. Report from the automated childhood Cancer information system project. Eur J Cancer. 2006;42(13):2124–35.CrossRef Stiller C, Bielack S, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978–1997. Report from the automated childhood Cancer information system project. Eur J Cancer. 2006;42(13):2124–35.CrossRef
4.
Zurück zum Zitat Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma overview. Rheumatol Ther. 2017;4(1):25–43.CrossRef Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma overview. Rheumatol Ther. 2017;4(1):25–43.CrossRef
5.
Zurück zum Zitat Fletcher CD, Unni KK, Mertens F. Pathology and genetics of tumours of soft tissue and bone, vol. 4: Iarc; 2002. Fletcher CD, Unni KK, Mertens F. Pathology and genetics of tumours of soft tissue and bone, vol. 4: Iarc; 2002.
6.
Zurück zum Zitat Porter D, Holden S, Steel C, Cohen B, Wallace M, Reid R. A significant proportion of patients with osteosarcoma may belong to Li-Fraumeni cancer families. J Bone Joint Surg Br Vol. 1992;74(6):883–6.CrossRef Porter D, Holden S, Steel C, Cohen B, Wallace M, Reid R. A significant proportion of patients with osteosarcoma may belong to Li-Fraumeni cancer families. J Bone Joint Surg Br Vol. 1992;74(6):883–6.CrossRef
7.
Zurück zum Zitat Hayden JB, Hoang BH. Osteosarcoma: basic science and clinical implications. Orthop Clin N Am. 2006;37(1):1–7.CrossRef Hayden JB, Hoang BH. Osteosarcoma: basic science and clinical implications. Orthop Clin N Am. 2006;37(1):1–7.CrossRef
8.
Zurück zum Zitat Amberger J, Bocchini CA, Scott AF, Hamosh A. McKusick’s online Mendelian inheritance in man (OMIM®). Nucleic Acids Res. 2009;37(suppl 1):D793–6.CrossRef Amberger J, Bocchini CA, Scott AF, Hamosh A. McKusick’s online Mendelian inheritance in man (OMIM®). Nucleic Acids Res. 2009;37(suppl 1):D793–6.CrossRef
9.
Zurück zum Zitat Maier H, Döhr S, Grote K, O’keeffe S, Werner T, de Angelis MH, Schneider R. LitMiner and WikiGene: identifying problem-related key players of gene regulation using publication abstracts. Nucleic Acids Res. 2005;33(suppl_2):W779–82.CrossRef Maier H, Döhr S, Grote K, O’keeffe S, Werner T, de Angelis MH, Schneider R. LitMiner and WikiGene: identifying problem-related key players of gene regulation using publication abstracts. Nucleic Acids Res. 2005;33(suppl_2):W779–82.CrossRef
10.
Zurück zum Zitat Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G, Liu Y. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res. 2009;37(suppl 1):D98–D104.CrossRef Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G, Liu Y. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res. 2009;37(suppl 1):D98–D104.CrossRef
11.
Zurück zum Zitat Li Y, Qiu C, Tu J, Geng B, Yang J, Jiang T, Cui Q. HMDD v2. 0: a database for experimentally supported human microRNA and disease associations. Nucleic Acids Res. 2013;42(D1):D1070.CrossRef Li Y, Qiu C, Tu J, Geng B, Yang J, Jiang T, Cui Q. HMDD v2. 0: a database for experimentally supported human microRNA and disease associations. Nucleic Acids Res. 2013;42(D1):D1070.CrossRef
12.
Zurück zum Zitat He X, Chang S, Zhang J, Zhao Q, Xiang H, Kusonmano K, Yang L, Sun ZS, Yang H, Wang J. MethyCancer: the database of human DNA methylation and cancer. Nucleic Acids Res. 2008;36(suppl 1):D836–41.PubMed He X, Chang S, Zhang J, Zhao Q, Xiang H, Kusonmano K, Yang L, Sun ZS, Yang H, Wang J. MethyCancer: the database of human DNA methylation and cancer. Nucleic Acids Res. 2008;36(suppl 1):D836–41.PubMed
13.
Zurück zum Zitat Wingender E, Chen X, Hehl R, Karas H, Liebich I, Matys V, Meinhardt T, Prüß M, Reuter I, Schacherer F. TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Res. 2000;28(1):316–9.CrossRef Wingender E, Chen X, Hehl R, Karas H, Liebich I, Matys V, Meinhardt T, Prüß M, Reuter I, Schacherer F. TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Res. 2000;28(1):316–9.CrossRef
14.
Zurück zum Zitat Poos K, Smida J, Nathrath M, Maugg D, Baumhoer D, Neumann A, Korsching E. Structuring osteosarcoma knowledge: an osteosarcoma-gene association database based on literature mining and manual annotation. Database (Oxford). 2014;2014:1–9. Poos K, Smida J, Nathrath M, Maugg D, Baumhoer D, Neumann A, Korsching E. Structuring osteosarcoma knowledge: an osteosarcoma-gene association database based on literature mining and manual annotation. Database (Oxford). 2014;2014:1–9.
15.
Zurück zum Zitat Sadikovic B, Yoshimoto M, Chilton-MacNeill S, Thorner P, Squire JA, Zielenska M. Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet. 2009;18(11):1962–75.CrossRef Sadikovic B, Yoshimoto M, Chilton-MacNeill S, Thorner P, Squire JA, Zielenska M. Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet. 2009;18(11):1962–75.CrossRef
16.
Zurück zum Zitat Walter I, Wolfesberger B, Miller I, Mair G, Burger S, Galle B, Steinborn R. Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS. Oncol Rep. 2014;31(3):1147–56.CrossRef Walter I, Wolfesberger B, Miller I, Mair G, Burger S, Galle B, Steinborn R. Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS. Oncol Rep. 2014;31(3):1147–56.CrossRef
17.
Zurück zum Zitat Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res. 2011;17(8):2110–9.CrossRef Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res. 2011;17(8):2110–9.CrossRef
18.
Zurück zum Zitat Namlos HM, Meza-Zepeda LA, Baroy T, Ostensen IH, Kresse SH, Kuijjer ML, Serra M, Burger H, Cleton-Jansen AM, Myklebost O. Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One. 2012;7(10):e48086.CrossRef Namlos HM, Meza-Zepeda LA, Baroy T, Ostensen IH, Kresse SH, Kuijjer ML, Serra M, Burger H, Cleton-Jansen AM, Myklebost O. Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One. 2012;7(10):e48086.CrossRef
19.
Zurück zum Zitat Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–10.CrossRef Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–10.CrossRef
20.
Zurück zum Zitat Gautier L, Cope L, Bolstad BM. Irizarry RA: affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307–15.CrossRef Gautier L, Cope L, Bolstad BM. Irizarry RA: affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307–15.CrossRef
21.
Zurück zum Zitat Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249–64.CrossRef Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249–64.CrossRef
22.
Zurück zum Zitat Smyth GK. Limma: linear models for microarray data. In: Bioinformatics and computational biology solutions using R and Bioconductor. NewYork: Springer; 2005. p. 397–420. Smyth GK. Limma: linear models for microarray data. In: Bioinformatics and computational biology solutions using R and Bioconductor. NewYork: Springer; 2005. p. 397–420.
23.
Zurück zum Zitat Storey JD. False discovery rate. In: International encyclopedia of statistical scienc. NewYork: Springer; 2011. p. 504–8. Storey JD. False discovery rate. In: International encyclopedia of statistical scienc. NewYork: Springer; 2011. p. 504–8.
24.
Zurück zum Zitat Matys V, Fricke E, Geffers R, Gößling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV. TRANSFAC®: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 2003;31(1):374–8.CrossRef Matys V, Fricke E, Geffers R, Gößling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV. TRANSFAC®: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 2003;31(1):374–8.CrossRef
25.
Zurück zum Zitat Consortium EP. The ENCODE (ENCyclopedia of DNA elements) project. Science. 2004;306(5696):636–40.CrossRef Consortium EP. The ENCODE (ENCyclopedia of DNA elements) project. Science. 2004;306(5696):636–40.CrossRef
26.
Zurück zum Zitat John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. PLoS Biol. 2004;2(11):e363.CrossRef John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. PLoS Biol. 2004;2(11):e363.CrossRef
27.
Zurück zum Zitat Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA–target interactions. Nucleic Acids Res. 2009;37(suppl 1):D105–10.CrossRef Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA–target interactions. Nucleic Acids Res. 2009;37(suppl 1):D105–10.CrossRef
28.
Zurück zum Zitat Wang X, El Naqa IM. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics. 2008;24(3):325–32.CrossRef Wang X, El Naqa IM. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics. 2008;24(3):325–32.CrossRef
29.
Zurück zum Zitat Dweep H, Sticht C, Pandey P, Gretz N. miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform. 2011;44(5):839–47.CrossRef Dweep H, Sticht C, Pandey P, Gretz N. miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform. 2011;44(5):839–47.CrossRef
30.
Zurück zum Zitat Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.CrossRef Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.CrossRef
31.
Zurück zum Zitat Sherry S, Ward M-H, Kholodov M, Baker J, Phan L, Smigielski E, Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308.CrossRef Sherry S, Ward M-H, Kholodov M, Baker J, Phan L, Smigielski E, Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308.CrossRef
32.
Zurück zum Zitat Seshan VE, Olshen AB. DNAcopy: a package for analyzing DNA copy data. R package version; 2013. Seshan VE, Olshen AB. DNAcopy: a package for analyzing DNA copy data. R package version; 2013.
33.
Zurück zum Zitat Zhang J, Feng B, Zhang MJ. biocViews microarray C: package ‘cghMCR’. R package version; 2013. Zhang J, Feng B, Zhang MJ. biocViews microarray C: package ‘cghMCR’. R package version; 2013.
34.
Zurück zum Zitat Ongenaert M, Van Neste L, De Meyer T, Menschaert G, Bekaert S, Van Criekinge W. PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res. 2007;36(suppl_1):D842–6.CrossRef Ongenaert M, Van Neste L, De Meyer T, Menschaert G, Bekaert S, Van Criekinge W. PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res. 2007;36(suppl_1):D842–6.CrossRef
Metadaten
Titel
Construction of an integrated human osteosarcoma database, HOsDb, based on literature mining, microarray analysis, and database retrieval
verfasst von
Yifu Sun
Lishan Wang
Changkuan Li
Rui Gu
Weidong Zang
Wei Song
Peng Xia
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2020
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-06719-2

Weitere Artikel der Ausgabe 1/2020

BMC Cancer 1/2020 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.